259 related articles for article (PubMed ID: 29868437)
21. Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.
Mito Y; Yabe I; Yaguchi H; Sato C; Takei T; Terae S; Tajima Y
Clin Neurol Neurosurg; 2020 Sep; 196():105960. PubMed ID: 32593043
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal DAT changes measured with [
Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
[TBL] [Abstract][Full Text] [Related]
23. Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson's disease.
Gigante AF; Asabella AN; Iliceto G; Martino T; Ferrari C; Defazio G; Rubini G
Neurol Sci; 2018 Mar; 39(3):551-555. PubMed ID: 29362953
[TBL] [Abstract][Full Text] [Related]
24. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.
Varrone A; Marek KL; Jennings D; Innis RB; Seibyl JP
Mov Disord; 2001 Nov; 16(6):1023-32. PubMed ID: 11748733
[TBL] [Abstract][Full Text] [Related]
25. Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease.
Roos DS; Twisk JWR; Raijmakers PGHM; Doty RL; Berendse HW
J Neural Transm (Vienna); 2019 Nov; 126(11):1471-1478. PubMed ID: 31515655
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy.
Sakakibara S; Hashimoto R; Katayama T; Kenjyo M; Yokokawa Y; Saito Y; Hirakawa A; Ito M; Nakamura T; Hara K; Hashizume A; Aiba I; Inukai A; Katsuno M
J Parkinsons Dis; 2020; 10(1):123-130. PubMed ID: 31707374
[TBL] [Abstract][Full Text] [Related]
27. The utility of the combined use of
Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
[TBL] [Abstract][Full Text] [Related]
28. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
Chahine LM; Siderowf A; Barnes J; Seedorff N; Caspell-Garcia C; Simuni T; Coffey CS; Galasko D; Mollenhauer B; Arnedo V; Daegele N; Frasier M; Tanner C; Kieburtz K; Marek K;
J Parkinsons Dis; 2019; 9(4):665-679. PubMed ID: 31450510
[TBL] [Abstract][Full Text] [Related]
29. Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD).
Suwijn SR; Samim H; Eggers C; Espay AJ; Fox S; Lang AE; Samuel M; Silverdale M; Verschuur CVM; Dijk JM; Verberne HJ; Booij J; de Bie RMA
J Parkinsons Dis; 2020; 10(4):1561-1569. PubMed ID: 32597819
[TBL] [Abstract][Full Text] [Related]
30. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT.
Nocker M; Seppi K; Donnemiller E; Virgolini I; Wenning GK; Poewe W; Scherfler C
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):1012-20. PubMed ID: 22460689
[TBL] [Abstract][Full Text] [Related]
31. Use of
Dongfang C; Xianzhi M; Cen L; Zhongke H
Hell J Nucl Med; 2022; 25(3):247-252. PubMed ID: 36507880
[TBL] [Abstract][Full Text] [Related]
32. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
Jenkins PO; Roussakis AA; De Simoni S; Bourke N; Fleminger J; Cole J; Piccini P; Sharp D
J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):631-637. PubMed ID: 32381639
[TBL] [Abstract][Full Text] [Related]
33. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
Im JH; Chung SJ; Kim JS; Lee MC
J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
[TBL] [Abstract][Full Text] [Related]
34. DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice.
Yomtoob J; Koloms K; Bega D
Parkinsonism Relat Disord; 2018 Aug; 53():37-41. PubMed ID: 29748111
[TBL] [Abstract][Full Text] [Related]
35. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.
Ravina B; Marek K; Eberly S; Oakes D; Kurlan R; Ascherio A; Beal F; Beck J; Flagg E; Galpern WR; Harman J; Lang AE; Schwarzschild M; Tanner C; Shoulson I
Mov Disord; 2012 Sep; 27(11):1392-7. PubMed ID: 22976926
[TBL] [Abstract][Full Text] [Related]
36. Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease.
Jaakkola E; Joutsa J; Mäkinen E; Johansson J; Kaasinen V
Eur J Neurol; 2017 Nov; 24(11):1341-1347. PubMed ID: 28834102
[TBL] [Abstract][Full Text] [Related]
37. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal clustering analysis and prediction of Parkinson's disease progression using radiomics and hybrid machine learning.
Salmanpour MR; Shamsaei M; Hajianfar G; Soltanian-Zadeh H; Rahmim A
Quant Imaging Med Surg; 2022 Feb; 12(2):906-919. PubMed ID: 35111593
[TBL] [Abstract][Full Text] [Related]
39. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
[TBL] [Abstract][Full Text] [Related]
40. Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
Muñoz-Delgado L; Labrador-Espinosa MÁ; Macías-García D; Jesús S; Benítez Zamora B; Fernández-Rodríguez P; Adarmes-Gómez AD; Reina Castillo MI; Castro-Labrador S; Silva-Rodríguez J; Carrillo F; García Solís D; Grothe MJ; Mir P
Mov Disord; 2023 May; 38(5):755-763. PubMed ID: 36912400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
